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Abstract: Due to the discovery of RNAi, oligonucleotides
(oligos) have re-emerged as a major pharmaceutical target
that may soon be required in ton quantities. However, it is
questionable whether solid-phase oligo synthesis (SPOS)
methods can provide a scalable synthesis. Liquid-phase
oligo synthesis (LPOS) is intrinsically scalable and amenable
to standard industrial batch synthesis techniques. However,
most reported LPOS strategies rely upon at least one precip-
itation per chain extension cycle to separate the growing oli-
gonucleotide from reaction debris. Precipitation can be diffi-
cult to develop and control on an industrial scale and, be-
cause many precipitations would be required to prepare
a therapeutic oligonucleotide, we contend that this ap-
proach is not viable for large-scale industrial preparation. We
are developing an LPOS synthetic strategy for 2’-methyl RNA
phosphorothioate that is more amenable to standard batch
production techniques, using organic solvent nanofiltration
(OSN) as the critical scalable separation technology. We
report the first LPOS-OSN preparation of a 2’-Me RNA phos-
phorothioate 9-mer, using commercial phosphoramidite
monomers, and monitoring all reactions by HPLC, 31P NMR
spectroscopy and MS.
Introduction
Oligonucleotides (oligos) have re-emerged as a major pharma-
ceutical target due to the unprecedented opportunity for con-
trolling protein expression mediated by short RNA oligomers
(ca. 20 nucleotides long) through RNA interference (RNAi) with
small interfering RNA (siRNA) or micro-RNA (miRNA), and these
have in turn re-invigorated research in the field of anti-sense
oligonucleotides (ASO/AS-ON).[1–3] Excitement rose with the
recent demonstration of safe and effective delivery of oligos in
humans.[4] This imperative has underlined the need for scalable
methods of RNA synthesis. Today the overwhelming majority
of oligos are prepared using solid-phase oligo synthesis
(SPOS), but this is very challenging to scale up.[5] We are devel-
oping a liquid-phase oligo synthesis (LPOS) synthetic strategy
that will be more amenable to standard batch production
techniques than SPOS,[6] using organic-solvent nanofiltration
(OSN) as the critical scalable technology for separating the
growing oligo from all other reagents.[7] We now report the
LPOS-OSN preparation of a 2’-methyl RNA phosphorothioate 9-
mer, monitoring all reactions by HPLC, 31P NMR spectroscopy
and MS.
The defining characteristic of SPOS is the ease of separation
of the growing oligo from excess reagents: the solid synthesis
support bed/column is simply washed with solvent to remove
any molecular species not covalently attached to it. SPOS has
been scaled up to 1–2 kg per batch,[5] and the largest trial of
the new generation of RNAi therapies required a few kg of
oligo.[5] Thus it is expected that 100s of kilograms of oligo
might be required annually to treat rare diseases, and possibly
tons for major ones. The leading companies in the field have
claimed that SPOS can be extended to yet larger scales.[8] How-
ever, the specialized equipment is demanding and expensive
to use in an industrial setting, and we believe that SPOS, even
with major advances, is incapable of approaching the 100 kg
scale per batch, because of the challenge of completely and
reproducibly washing large beds of synthesis support.[9a] There-
fore a very serious gap is expected to open between oligo
supply and demand that will restrict this otherwise promising
new mode of therapy. Consequently, a new method of oligo
production is urgently required.
Early on scalability was identified as the Achilles’ heel of
SPOS, and LPOS has long been proposed to overcome this
problem.[10] However, the critical question that must be ad-
dressed in any LPOS strategy is how to separate the growing
oligo from excess reagents and byproducts. So far, amongst
the alternative strategies reported for the synthesis of oligos,
chromatography has been dismissed as too time-consuming,
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solvent intensive, and inefficient.[11] Whilst approaches includ-
ing size-exclusion chromatography[12] and extraction[13] have
been proposed to overcome this separation problem, precipi-
tation of polymer-supported oligo has been explored much
more widely. Initially DNA oligos supported on poly(styrene)
(the same solid-phase support as had recently been used by
Merryfield for peptide synthesis)[14] were assembled by means
of Khorana’s phosphodiester approach.[10,15] Subsequent au-
thors explored poly(vinyl alcohol) (PVA)[16,17] and cellulose[18] as
supports, but poly(ethylene glycol) came to dominate this
strategy wherein the oligonucleotidyl-PEG was usually precipi-
tated with diethyl ether.[17,19–21] Recently a discrete, non-poly-
meric synthesis support was developed in which four oligo
chains were grown simultaneously around a pentaerythritol
core, and the products were then precipitated from
methanol.[22,23]
Whilst approaches to oligo synthesis based upon precipita-
tion or crystallisation are in theory scalable, it is questionable
whether this would be truly practical. Process development of
industrial precipitation is often time-consuming and labour-in-
tensive, with the conditions being unique to each com-
pound.[9b] During Bonora’s preparation of 10 mg DNA 20-
mer,[20] 79 separate precipitations and crystallisations were re-
quired. Furthermore, it is inevitable that material will always be
lost to incomplete separation: on the PEG support it was
found that losses, starting around 1% per cycle, became more
significant as the increasing solubility of the growing oligo
began to overwhelm the polymer-driven phase separation;[20]
during the preparation of an RNA 5-mer on the small pentaery-
thritol support, the coupling cycle yield only averaged 85% for
a 54% overall yield, which would be unacceptable for com-
mercial production.[23]
The use of membrane-based technologies for the separation
of synthetic biopolymers has been little explored, despite their
evident potential to realise scalable liquid-phase approaches to
valuable targets. In the first such synthesis, Bayer and Mutter
bound peptides to mono-methyl PEG-10000 (mPEG) that was
purified by ultrafiltration.[24] This approach was repeated for
oligos by the same laboratory, using the now obsolete phos-
phodiester coupling strategy and either PVA or PEG-10000
polymeric supports.[17] However, there was no further develop-
ment of this approach for either biopolymer. Alternation be-
tween chain extension in organic solvent and diafiltration in
water after each chain extension cycle probably makes this
strategy impractical.
We postulated that organic-solvent nanofiltration (OSN)
could fulfil the critical separation role in an LPOS strategy con-
ducted entirely in organic solution, Figure 1. Furthermore,
since organic-solvent stable nanofiltration (as opposed to ultra-
filtration) membranes are now available, we proposed that
a smaller, discrete synthesis support could be used. During
OSN, solutes are separated by size exclusion and geometric se-
lection as they pass through a membrane possessing nanome-
ter-scale permeation pathways. Solutes that cannot pass
through the membrane are said to be rejected and remain in
the upstream retentate. This scalable technology is fully com-
patible with a pharmaceutical industry batch reactor. We fur-
ther postulated that LPOS-OSN would provide an excellent
platform for monitoring the ongoing oligo synthesis, by means
of sampling using a simple liquid draw-off. Although in princi-
ple it is also possible to monitor chain extension progress with
SPOS, we are unaware of any report of such a procedure. This
is most likely due to the difficulty of engineering repeated
access to beds of solid support in large diameter, pressurized
steel columns (columns for preparing 1–2 kg oligo by SPOS
have diameters 50–100 cm and pressure ratings of 15–20 bar).
Ready access to samples, although providing the opportunity
to optimize reactions and to rescue failed steps, is of marginal
value on the small synthetic scales regularly produced today.
However, in the future, during the preparation of tens of kilo-
grams to tons of oligos, it would be economically unaccepta-
ble to risk the complete loss of such large batches of very ex-
pensive building blocks without critical quality control.
Selection of LPOS-OSN materials
Building on our earlier experience with membrane-enhanced
peptide synthesis (MEPS) in organic solvent (DMF),[25] we initial-
ly explored OSN separation of mPEG-5000-supported dinucleo-
tides.[26] However, even a,w-bis(dinucleotidyl)-PEG-10000 had
too low a rejection for practical LPOS-OSN. Therefore we in-
Figure 1. The LPOS-OSN concept: a) Chain extension reaction; b) diafiltration
by OSN to remove excess reagents; c) 5’-O deprotection; d) diafiltration by
OSN to remove excess reagents, then repeat cycle to the desired length.
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stead adopted monodisperse tris(octagol) homostar 1 (a ho-
mostar is a star polymer in which all the arms are identical) as
a branched LPOS support, see Scheme 1.[27] We hypothesised
that this would have three advantages: 1) branching should in-
hibit threading of the supported oligo into the membrane per-
meation pathways, and therefore increase membrane rejection
of the construct;[28] 2) with three oligos growing around one
hub, the molecular weight will rise by three nucleotides per
cycle, rapidly increasing the overall size, and hence the rejec-
tion of the tris(oligonucleotidyl) support with oligo length; and
3) since the tris(oligonucleotidyl) support is a discrete species,
HPLC and mass spectral (MS) analyses of real-time synthetic
quality should be feasible.
We next required an OSN membrane compatible with aceto-
nitrile, the solvent in which phosphoramidite couplings are
typically conducted. The membrane should also be compatible
with feed mixtures containing typical oligo coupling, oxida-
tion/thioylation, capping and 5’-O-unblocking reagents. Fur-
thermore, the membrane must be able to permeate nucleotide
monomer debris after oligo chain extension; these species are
the largest molecular weight debris generated during the syn-
thesis cycle. To meet these challenges we developed a new
class of OSN membrane (PBI-17DBX), prepared from poly(ben-
zimidazole) and cross-linked with para-dibromoxylene. PBI-
17DBX is very resistant to chemical degradation and gave
highly reproducible performance in CH3CN, whilst being open
enough to allow species of similar size to nucleotide mono-
mers to permeate.[29]
Second- and third-generation therapeutic oligos most com-
monly contain either 2’-deoxy or 2’-modified nucleosides (e.g. ;
CH3O-, CH3OCH2CH2O-, F-), as well as more complex locked/
bridged ribose analogues.[30–32] For this reason we elected to
focus on nucleic acid analogues for our LPOS-OSN test se-
quence, instead of native RNA. Adoption of LPOS-OSN by
other groups would be encouraged if this technology was
compatible with commercial building blocks and common pro-
tective group combinations. Therefore we selected readily
available 2’-methoxy nucleosides, activated as their 2-cya-
noethyl (Cne) N,N-diisopropylphosphoramidites, carrying 5’-O-
(4,4’-dimethoxytriphenylmethyl) (Dmtr) temporary protection
and with various amides blocking the exocyclic amino groups
of the nucleobases.[5] We also selected the widely used, first-
generation phosphorothioate modification as a target for this
pilot project because the debris from thioylation reagents is
likely to be a more severe test of LPOS-OSN purification than
common oxidants (e.g. iodine–pyridine–water, or tert-butyl
hydroperoxide).
All previous LPOS studies, except for that of Lonnberg,[23]
have concerned the synthesis of DNA oligos, which are easier
to prepare than RNA. Furthermore, with the exception of Bo-
nora’s DNA 20-mer prepared using numerous precipitations
and crystallisations,[19] the largest oligo prepared by LPOS to
date using iterative synthesis is a DNA 10-mer, through H-
phosphonate coupling;[21] a DNA phosphorothioate 15-mer has
also been reported, but this was constructed using dimer
building blocks.[20] As a challenging target for this new LPOS-
OSN technology, we set out to synthesise a 2’-methyl RNA
phosphorothioate 9-mer section of the M23D ASO.[33] To assess
the performance of the support and phosphoramidite chemis-
try in this new environment, we planned to undertake global
deprotection at both the 5-mer (four chain extensions) and 9-
mer (eight chain extensions) stages.
Results and Discussion
Homostar 1 was first condensed with 4.5 equivalents 5’-Dmtr-
2’-methyl-3’-succinyl uridine (2, Dmtr-mU-Suc-OH), see
Scheme 1. Classical activation with 8 equivalents N,N’-diiso-
propyl carbodiimide, in addition to catalytic 4-(dimethylamino)-
pyridine (DMAP, 0.2 equiv) in THF, was incomplete with excess
Scheme 1. Homostar loading and synthesis of oligonucleotidyl homostars.
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uridine succinate being consumed as the acyl urea. To maxi-
mize the analytical potential of LPOS-OSN it is highly desirable
to drive loading of the synthesis support to completion to give
a homogeneous product, as well as to avoid waste of expen-
sive excess nucleoside on a large scale. Thus, condensation of
4.5 equivalents uridine succinate (2) with homostar 1 was initi-
ated with more reactive 2,6-dichlorobenzoyl chloride (DcbCl)
and N-methyl imidazole (NMI),[34] after which no PEG-terminal
hydroxyls remained. The resultant tris-Dmtr-ether (3) was then
detritylated with dichloroacetic acid (DCA), using pyrrole as
a cation scavenger,[35] to provide fully loaded homostar 4 in
80% yield over the two steps, ready to commence the chain
extension cycle. At this stage a small amount of Dcb-ester (5)
was separated chromatographically from 4 ; although this con-
taminant would not affect oligo synthesis at all, in this study it
was removed to simplify HPLC analysis of chain extension.
The loaded synthesis support 4 (1.24 g) was next chain ex-
tended with 5’-Dmtr-2’-methyl N-acetylcytidine (Dmtr-mC)
phosphoramidite 6C (1.5 equiv per OH) to mUmC homostar 7
under typical conditions, see Scheme 1: ethylthiotetrazole (ETT,
3 equiv per OH) in CH3CN, 35 min, then phenylacetyl disulfide
(PADS) in pyridine, 30 min, monitoring by HPLC (see Scheme 1
and Supporting Information). For this pilot study unusually
long times were used for both coupling and thioylation so
that the reactions could be sampled and monitored in real
time before moving on to the next process. For this reason,
the widely used ETT (pKa 4.3, 0.25m in CH3CN) was selected as
the activator, firstly because it is a compromise that provides
higher activity than classical tetrazole (pKa 4.8), but less than 4-
nitrophenyl tetrazole (NPT, pKa 3.7).
[36] Secondly, in larger scale
couplings with 2’-methyl phosphoramidites, 0.5m ETT has
proved effective over 5–15 min reaction times,[37] so 0.25m ETT
is commensurate with our longer reactions. Furthermore, al-
though NPT has been reported to give very high coupling
yields with 2’-methyl phosphoramidites,[38] we were concerned
that the greater acidity of this activator than ETT would exacer-
bate contamination from double coupling during the long re-
action times used here.
During SPOS mass transfer occurs between the bulk solution
and the solid support. For fast reactions, such as phosphorami-
dite coupling, mass transfer is the rate-limiting step.[9a,24] Thus,
if the same chemistry is used in both cases, yields in LPOS are
expected to be higher than in SPOS. Consequently, in an LPOS
strategy capping should not be as critical as in SPOS, and this
step was omitted simplifying the process during pilot study
development. Indeed, it is hoped that assay of the chain exten-
sion reaction will in future permit identification of otherwise
economically catastrophic failed couplings on very large scales,
and provide the opportunity to repeat the reaction. However,
if capping were implemented before the assay, it would then
be impossible to recover a failed coupling.
Once chain extension and thioylation were complete, the
crude mixture was then diluted with CH3CN, and poured di-
rectly into the OSN apparatus (see Supporting Information).
The rig was pressurized with nitrogen to force solvent and sol-
utes through the PBI-17DBX membrane, a process termed “dia-
filtration”. A constant volume of retentate was maintained
throughout diafiltration. Thus, the efficiency of OSN can be re-
lated to how many retentate system volumes, or “diavolumes”,
must be permeated to achieve a given degree of purification
of the retentate.
After 12 diavolumes, all small molecules had been removed
from the retentate. However, along with the desired Dmtr-di-
nucleotidyl homostar (7), most of the building block related
species, consisting of a mixture of amidates (8) and thioate
salts (9), were retained (corresponding to Nn-OP in Figure 1).
Notably, the proportion of phosphoryl species 8b and 9b
compared to thioyl derivatives 8a and 9a (P=O vs. P=S), deter-
mined by 31P NMR spectroscopy of the mixture (see Figure 2a),
increased substantially when the amount of PADS was reduced
from 10 to 3 equivalents per 5’-OH. Indeed, thioamidate 8a
was almost undetectable when the intermediate phosphite
was thioylated with 3 equivalents PADS, although amidate 8b
rose to between 15 and 25% of the 31P NMR signal integral in-
tensity of product 7.
The crude tris(mUmC-Dmtr) homostar 7 was washed from
the OSN rig and re-dissolved in CH2Cl2. To this were added pyr-
role then DCA, and after 30 min the detritylation was complete
by HPLC. Unlike in SPOS, in which the detritylation equilibrium
is driven to completion by flushing the Dmtr+ cation away
from 5’-OH oligo bound to the solid support, in solution phase
a scavenger (here pyrrole[35]) is necessary to ensure total un-
blocking. Otherwise even small amounts of mono-tritylated ho-
mostar would be carried through to the next cycle where
(even after capping) subsequent detritylation would lead to
n¢1 short-mers. It had been anticipated that at this stage the
smaller fragments from the excess building block (Dmtr-pyr-
role, and 5’-OH amidates 11 and thioates 12, now correspond-
ing to P and Nn-OH in Figure 1) would then permeate, but
Figure 2. OSN of dinucleotidyl homostar monitored by 31P NMR spectrosco-
py: a) Tris(mUmC-Dmtr) homostar 7 after permeating 12 diavolumes of
CH3CN—apart from the homostar, amidates 8a and 8b, and thioate salts 9a
and 9b are present; b) tris(mUmC-OH) homostar 10 after permeating 5 dia-
volumes 1% DCA-CH3CN and 10 diavolumes CH3CN; c) expansion of b) ex-
hibiting the two diastereoisomers of the internucleotide linkage, plus a low
level of possible N-deacetylation of cytosine (see Supporting Information).
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they did not. Suspecting that ion exchange could occur be-
tween the protonatable PBI membrane surface and thioate
salts 12, 1 vol% DCA was added to the first five diavolumes.
After a total of 15 diavolumes had permeated the product tris-
(mUmC-OH) homostar 10 was then of a similar purity to that
achieved by flash chromatography. However, the detritylated
amidates (11) were slower to permeate than the thioate salts
12, and thioamidate 11a exhibited substantially greater rejec-
tion than amidate 11b. Thus by reducing the excess of PADS
from 10 to 3 equivalents, when very little or no thioamidate
11a formed, the purity of dinucleotidyl homostar 10 was maxi-
mised (Figure 2b). Dmtr-pyrrole was the only contaminant sig-
nificantly rejected by PBI 17DBX (see HPLC in Supporting Infor-
mation). Thus, although Dmtr-pyrrole probably does not inter-
fere with subsequent couplings, this was removed by precipi-
tation of tris(mUmC-OH) homostar 10 in diethyl ether so that
an accurate mass recovery could be determined; apart from
Dmtr-pyrrole no other species could be detected in the super-
natant by 1H or 31P NMR spectroscopy. After the first chain ex-
tension cycle a moderate 75% yield of tris(mUmC-OH) homo-
star 10 was isolated. The only detectable impurity was a low
level of cytosine N-deacetylation, identified by LC-MS (see Sup-
porting Information) and believed to be the minor peaks in
Figure 2c.
Despite the need to remove Dmtr-pyrrole by precipitation,
the above cycle was repeated on homostar 10, see Scheme 2;
from this point on, all chain extension cycles start with 1.2–
1.4 g tris(5’-HO-oligo) homostar. Thus, after chain extension,
Dmtr-3-mer homostar 13 was partially purified by OSN (12 dia-
volumes) then detritylated, after which all the nucleotidyl
debris was separated by OSN, and precipitation was again
used to remove residual Dmtr-pyrrole. This time during the
second diafiltration, the first five diavolumes contained only
0.1% DCA to minimize N-deacetylation. The 85% yield of tris-
(mUmCmC-OH) homostar 14 was significantly higher than that
of dinucleotidyl homostar 10 at the same stage (see Scheme 2,
inset graph), indicating that as expected the homostar rejec-
tion had risen with oligo length. It should be noted that chain
extension cycle yields are calculated assuming 100% purity of
the product homostar. However, as low levels of side-reactions
accumulate on the growing oligo, the purity cannot be 100%,
so the molecular weight cannot be precisely defined, and the
yields are more correctly referred to as apparent yields.
Both the tritylated (13) and detritylated (14) tris(trinucleotid-
yl) homostars were less soluble in CH3CN than the shorter spe-
cies 4, 7 and 10—a trend that continued with increasing
length. Noting that all the oligonucleotidyl homostars (14–18
and 20–27) were highly soluble in DMF, all subsequent phos-
phoramidite couplings were conducted in CH3CN–DMF (ca.
9:1) ; this solubility of a branched 2’-Me-RNA 24-mer oligonu-
cleotidyl homostar (18) may be favorably contrasted with the
previously reported poor solubility of 5’-OH DNA 8-mers in
CH3CN.
[39] The solvent was also changed during OSN from neat
CH3CN, in which tris(tetranucleotidyl) homostar 16 is almost in-
soluble, to CH3OH–CH3CN (1:4 or 1:3 v/v) in which all the oligo-
nucleotidyl homostars are soluble up to at least tris(9-mer) ho-
mostar 27 (0.4 wt% 27 during final diafiltration; the saturation
conc. was not determined). Finally, the DCA in the second dia-
filtration was replaced by 1% pyridinium dichloroacetate
(Py·DCA) which promoted permeation of thioate salts 12 just
as effectively as un-buffered DCA. This protocol was used on 4-
mer 16 and for all later chain extension cycles, following each
reaction by HPLC, and assaying the products by 31P NMR spec-
troscopy and MALDI MS, both before and after detritylation
(see Supporting Information).
Two further rounds of chain extension were conducted, with
the apparent yield continuing to rise (82% 16, 94% 18, see
inset graph, Scheme 2). Although HPLC usefully exhibited re-
tention times lengthening in relation to the number of 5’-Dmtr
ethers per homostar, both during chain extension and detrity-
lation, by 5-mers 17 and 18 the peaks were too broad to be of
Scheme 2. Chain extension cycle. Inset : Change in apparent yield of isolated
5’-OH tris(oligonucleotidyl) homostar with oligo length.
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further analytical use (see Supporting Information), presumably
due to the exponentially growing number of diastereoisomers
at the P-centers of the oligo backbone. However, 31P NMR
spectroscopy continued to demonstrate acceptably low levels
of amidate contamination after each cycle. Furthermore, MS
confirmed that full-length tris(mUmCmCmAmU-OH) homostar
18 was the principal product. By contrast, MS of an oligo con-
jugated to a polydisperse support would be spread over too
many polymeric homologues to provide sufficiently intense
peaks for analysis.
Pentanucleotidyl homostar 18 was deprotected first with di-
ethylamine, then overnight in aqueous ammonia at 55 8C. The
following day, trituration with CH3CN removed protective
group debris to give crude 2’-methyl RNA phosphorothioate 5-
mer 19. HPLC assay of this material (Figure 3a) exhibited
a moderate purity of 74%, with both short-mer and long-mer
contaminants. Although these short-mers could be explained
by lack of capping, we believe that they actually derive from
chain extension of residual amidate building block 11 after
OSN. Examination of the mass spectra of the 5’-OH tris(oligo-
nucleotidyl) homostars 10, 14, 16 and 18 (from 2-mer to 5-
mer) exhibit no detectable ions corresponding to incomplete
chain extension. Since our synthesis support possesses three
arms, if 1% incomplete chain extension had occurred, this
would afford approximately 3% homostar having one arm
bearing the n¢1 short-mer. Thus, assuming that MALDI ioniza-
tion of full-length oligohomostars and their singly truncated
oligohomostar contaminants are similar, mass spectral analysis
of homostars supported oligonucleotides should usefully am-
plify sequence errors to detectable amounts. The long-mers
probably arise from two sources: 1) relatively long coupling
times compared to SPOS (35 min vs. 6–12 min) were used here
to allow time for HPLC confirmation of complete coupling.
This favors double coupling due to ETT induced detritylation.[40]
2) N-Deacetylation of cytosine residues (as observed at the
dimer stage) could provide sites for branching, although we
suspect that the switching from DCA to Py·DCA in the second
diafiltration of each cycle largely suppressed this.
Chain extension was continued from tris(pentanucleotidyl)
homostar 18 with the same protocol for another four cycles,
and 31P NMR spectroscopy and MS now served as the principal
methods of product characterization, to obtain 1.36 g of the
desired tris(nonanucleotidyl) homostar 27. Apparent yields of
detritylated 6- to 9-mer homostars 21, 23, 25 and 27 now pla-
teaued around an average of 95% (see inset graph, Scheme 2).
Finally, at the 9-mer stage MS indicated incomplete coupling
with approximately 90% conversion per chain (25!26). This
material was detritylated and deprotected as before to charac-
terize the crude 9-mer by HPLC (Figure 3b); 266 mg 5’-OH 9-
mer homostar 27 gave 180 mg crude 9-mer 28. As implied by
the homostar MS, HPLC indicated 49% of the desired 9-mer
28, plus 17% of the expected 8-mer impurity 29 (confirmed by
LC-MS, see Supporting Information). The 9-mer was then frac-
tionated for confirmatory analysis through two ion-exchange
columns to 94% purity (Figure 3c), and desalted providing
a 16% (29 mg) yield of pure 9-mer 28 from 5’-OH homostar
27. This material displayed identical HPLC (Figure 3d) and MS
to 9-mer 28 prepared by SPOS.
Conclusion
In this report we have demonstrated for the first time a new
liquid-phase synthesis and separation paradigm for oligonucle-
otides: liquid-phase oligonucleotide synthesis/organic-solvent
nanofiltration, LPOS-OSN. This was used to prepare 2’-methyl
RNA phosphorothioate 9-mer 28. This promising technology
has yet to equal the speed and purity of SPOS, requiring
around two days per chain extension cycle with the limited
area available from current laboratory-scale flat membrane
cells. However, the fact that we were able to perform eight
chain extension and detritylation cycles, with intermediate pu-
rifications, all in the liquid phase demonstrates that it has high
potential. Compared to competing precipitation strategies,
LPOS-OSN is more amenable to industrial exploitation because
liquid-phase handling is intrinsically scalable. LPOS-OSN also
has the major advantage over SPOS that it is straightforward
to sample and monitor every step of the process. Apart from
31P NMR spectroscopy and HPLC, the choice of a monodisperse
support also allowed characterization of the growing oligonu-
cleotidyl homostars by MS.
From the above experience, several modifications can be
suggested to improve future protocols : Shortening the cou-
pling time, and analysing only after thioylation, will reduce
long-mer formation.[40] Minimising 5’-unblocking time, and
therefore acid exposure, will minimise cytosine deacetylation,
and again possible long-mer formation. Biasing building block
debris away from amidates (8/11) into thioates (9/12) that are
more easily removed by diafiltration would suppress short-mer
formation. The overall yield of fully protected 5’-OH tris(oligo-
nucleotidyl) homostar 27 from loaded uridine homostar 4 is
only about 39%, mainly due to poor recovery from the early
cycles of OSN; the first three couplings (4!4-mer 14) give
a cumulative yield of only 52%, but the next five couplings (4-
Figure 3. HPLC of deprotected oligos: a) crude 5-mer 19, 75% purity;
b) crude 9-mer 28, 49%, containing 8-mer 29, 18%; c) purified 9-mer 28,
94%, from LPOS-OSN; d) 9-mer 28, 95%, from SPOS.
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mer 18!9-mer 27) have a combined yield of about 76%. This
will be much improved using our recently developed 2-stage
diafiltration; we would expect early stage recovery to be
>95% and from 5-mer onwards >99%.[41] As with SPOS,
LPOS-OSN consumes a lot of solvent. We have recently demon-
strated that an additional stage of diafiltration with a low-mo-
lecular-weight cut-off membrane can be used to recycle the
permeate solvent, greatly reducing the potential cost on an in-
dustrial scale.[42] As the scale of LPOS-OSN increases, an alterna-
tive analysis to direct HPLC of the retentate will be required;
we believe that rapid ammonia-methylamine (AMA) global de-
protection, followed by HPLC of the crude unblocked oligo will
provide a suitable method to assay for complete chain exten-
sion.[43] Finally, identifying a membrane that permeates Dmtr
derivatives, or using a smaller 5’-protecting group, such as the
methoxyisopropylidene acetal,[23] would make the process
even more efficient.
Experimental Section
General experimental details
1H and 13C NMR spectra were recorded on Brìker AV-400 or Brìker
AV-500 spectrometers. Chemical shifts in ppm are referenced with
respect to residual solvent signals: dH (CHCl3) 7.25 ppm, dH
(CHD2OD) 3.31 ppm, dH (CD3COCHD2) 2.05 ppm; dC (CDCl3)
77.50 ppm, dC (CD3OD) 49.15 ppm, dC (CD3COCHD2) 29.92 ppm.
The splitting patterns for 1H NMR spectra are denoted as follows;
s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), m
(multiplet), br (broad) and combinations thereof. Coupling con-
stants (J) are in Hertz (Hz). 13C NMR assignments (C, CH, CH2 and
CH3) and
1H NMR assignments were established with the aid of
DEPT-135, HSQC and COSY experiments. Molecular fragments not
abbreviated in main text are denoted as follows: U, uracil ; C, cyto-
sine; Ri, ribose; Suc, succinate; Hub, C6H3(CH2OR)3. CDCl3 was pur-
chased from VWR, and CD3OD and CD3COCD3 from Merck. NMR
spectrscopy of small Dmtr derivatives was conducted in the pres-
ence of either a small amount of Et3N or of pyridine. Mass spectra
were recorded on Micromass MALDI micro MX, or Micromass LCT
Premier (ESI) mass spectrometers. Phosphoramidites and 2’-O-
methyl uridine were purchased from Fisher Scientific Ltd. , UK or
ChemGenes Corp., USA. Other reagents were purchased from
Sigma-Aldrich Ltd. and used as supplied, except where specified.
Reactions were carried out under anhydrous conditions under a ni-
trogen atmosphere. Dichloromethane, acetonitrile, THF and DMF
were dried and stored over baked 4 æ molecular sieves. Triethyla-
mine, diethyl ether, methanol, isopropanol and N-methyl imidazole
were used as supplied. Flash chromatography was conducted in
a 9 cm diameter, porosity 3 glass sinter funnel: GeduranÒ (Si 60)
from Merck was used for normal phase columns, and Merck silan-
ised silica for reverse phase columns. Thin-layer chromatography
was carried out using Merck silica gel 60 F254 aluminium-backed
plates; compounds were visualised using UV light or KMnO4 stain.
Solid phase oligonucleotide synthesis (SPOS) was carried out on
a GE AKTA Oligopilot 10, using preloaded 2’OMe U Primer Support
200 and manufacturer’s standard protocols on a 30 mmol scale.
Cleavage from solid support and deprotection of nucleobases was
carried out in 0.88 aqueous ammonia at 55 8C for 16 h.
Synthetic procedures
Tris-1,3,5-{w-[2’-O-methyl-5’-O-(4’’,4’’’-dimethoxytriphenylmethy-
l)uridine-3’-O-succinyloxy]octa(ethylene glycol)-a-oxymethyl}-
benzene (3): Compound 1 (1.125 g, 1.00 mmol) was co-evaporated
from CH3CN (3Õ15 mL), re-dissolved in CH2Cl2 (7 mL) and a drop-
ping funnel was fitted to the flask. 2’-O-Methyl-3’-O-succinyl-5’-O-
(4’’,4’’’-dimethoxytriphenylmethyl)uridine, triethylammonium salt
(2, 3.047 g, 4.00 mmol) was co-evaporated from THF (3Õ50 mL),
then re-dissolved in CH2Cl2 (14 mL) and N-methylimidazole
(0.63 mL, 7.9 mmol) then 2,6-dichlorobenzoyl chloride (DcbCl,
0.54 mL, 3.77 mmol) were added. After stirring for 20 min, the acti-
vated succinate solution was transferred to the dropping funnel,
rinsing out the flask with further CH2Cl2 (5 mL), and this solution
slowly added to homostar 1 over 45 min. After stirring over night
the reaction was diluted with CH2Cl2 (250 mL) and extracted with
sat. NaHCO3 (200 mL). The aqueous layer was back-extracted with
small portions of CH2Cl2 (50 mLÕ3), the combined organic layers
dried over Na2SO4, and the solvent stripped off in vacuo. The resid-
ual foam may be purified chromatographically by fractionation
through a column of silanised silica, eluting with a gradient of
CH3CN–water (3:7 to 8:2 v/v containing 0.5% sat. NaHCO3), but
was normally used without purification. Rf (EtOH–CHCl3 1:9 + trace
Et3N) 0.56;
1H NMR (400 MHz, CDCl3): d=7.88 (d, J=8.2 Hz, 3H; U
CH), 7.38–7.36 (m, 6H; Dmtr CH), 7.32 (t, J=7.5 Hz, 6H; Dmtr CH),
7.29–7.24 (m, 18H; Hub CH + Dmtr CH), 6.86 (d, J=8.9 Hz, 12H;
Dmtr CH), 6.04 (d, J=3.7 Hz, 3H; 1’-CH), 5.33 (d, J=8.2 Hz, 3H; U
CH), 5.29 (t, J=5.6 Hz, 3H; 3’-CH), 4.55 (s, 6H; Hub-CH2O), 4.26–
4.24 (m, 9H; 4’-CH + Suc-OCH2), 4.10 (dd, J=5.1, 3.7 Hz, 3H; 2’-
CH), 3.81 (s, 18H; OCH3), 3.71–3.58 (m, 93H; CH2O + 5’-CHH), 3.48–
3.44 (m, 12H; 2’-OCH3 + 5’-CHH), 2.73–2.66 ppm (m, 12H; Suc
CH2) ;
13C NMR (101 MHz, CDCl3): d=171.98 (3C; Suc C=O), 171.53
(3C; Suc C=O), 163.29 (3C; U C), 158.73 (6C; Dmtr C), 150.30 (3C;
U C), 144.13 (3C; Dmtr C), 139.78 (3C; U 6-CH), 138.57 (3C; Hub C),
134.98 (3C; Dmtr C), 134.86 (3C; Dmtr C), 130.17 (6C; Dmtr CH),
130.09 (6C; Dmtr CH), 128.08 (12C; Dmtr CH), 127.24 (3C; Dmtr
CH), 126.32 (3C; Hub CH), 113.33 (12C; Dmtr CH), 102.51 (3C; U 5-
CH), 87.39 (3C; Dmtr C), 87.13 (3C; 1’-CH), 82.18 (3C; Ri CH), 81.03
(3C; Ri CH), 73.06 (3C; Hub-CH2O), 70.54 (39C; CH2O), 70.36 (3C; Ri
CH), 69.51 (3C; CH2O), 69.02 (3C; CH2O), 63.94 (3C; CH2O), 61.56
(3C; 5’-CH2), 59.03 (3C; 2’-OCH3), 55.26 (6C; Dmtr OCH3), 28.88
(3C; Suc CH2), 28.83 ppm (3C; Suc CH2) ; MS (MALDI-ToF+): m/z
calcd for [C162H210N6NaO57]
+ : 3175.4; found: 3176 [3+Na]+ .
Tris-1,3,5-[w-(2’-O-methyluridine-3’-O-succinyloxy)octa(ethylene
glycol)-a-oxymethyl]benzene (4): The crude tris(Dmtr-mU) homo-
star 3 (4.438 g from the above procedure) was dissolved in CH2Cl2
(40 mL) and pyrrole (1.39 mL, 19.6 mmol) was added. Dichloroace-
tic acid was then added in aliquots (0.40 mL, 4.8 mmol) until
a strong orange colour remained, and then dissipated over 20 min;
four aliquots were required to overwhelm buffering of the crude
Dmtr ether and TLC confirmed complete unblocking of intermedi-
ate 3. The reaction was diluted with CH2Cl2 (200 mL) and parti-
tioned with sat. NaHCO3 (150 mL). The aqueous layer was back-ex-
tracted with CH2Cl2 (50 mLÕ4), organic layers combined, dried
over Na2SO4 and the solvent stripped off under reduced pressure.
The residue was fractionated through a column of silica gel
(180 mL) in a large sinter funnel, eluting with a gradient of CH3OH–
CHCl3 (2:98 to 11:89 v/v). Bands containing Dcb-ester 5 (409 mg),
mixed with some product, and compound 4 (1.644 g, 80%) were
isolated as colourless gums. Rf (CH3OH–CHCl3 1:9) 4 0.35; 5 0.51;
1H NMR (400 MHz, CDCl3): d=9.53 (brd, J=2.3, 3H; U 4-NH), 7.85
(d, J=8.1 Hz, 3H; U 6-CH), 7.23 (s, 3H; Hub CH), 5.85 (d, J=5.1 Hz,
3H; 1’-CH), 5.76 (dd, J=8.0, 2.0 Hz, 3H; U 5-CH), 5.32 (t, J=4.6 Hz,
3H; 3’-CH) 4.55 (s, 6H; Hub-CH2O), 4.26 (dt, J=5.4, 2.0 Hz, 6H; Suc-
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OCH2), 4.22–4.19 (m, 6H; 4’-CH + 2’-CH), 3.94 (brd, J=12.0 Hz, 3H;
5’-CHH), 3.79 (brdd, J=12.3, 4.0 Hz, 3H; 5’-CHH), 3.72–3.61 (m,
90H; CH2O), 3.43 (s, 9H; 2’-OCH3), 2.76–2.68 ppm (m, 12H; Suc
CH2CH2) ;
13C NMR (101 MHz, CDCl3): d=172.08 (3C; Suc C=O),
171.68 (3C; Suc C=O), 163.92 (3C; U C), 150.75 (3C; U C), 141.22
(3C; U 6-CH), 138.51 (3C; Hub C), 126.29 (3C; Hub CH), 102.64 (3C;
U 5-CH), 88.69 (3C; 1’-CH), 83.18 (3C; 2’/4’-CH), 81.43 (3C; 2’/4’-
CH), 73.00 (3C; Hub-CH2O), 70.96 (3C; 3’-CH), 70.48 (39C; CH2O),
69.46 (3C; CH2O), 68.96 (3C; CH2O), 63.90 (3C; SucO-CH2), 61.15
(3C; 5’-CH2), 58.90 (3C; 2’-OCH3), 28.95 ppm (6C; Suc CH2CH2) ; MS
(MALDI-ToF+): m/z calcd for [C99H156N6NaO51]
+ : 2268.97; found:
2269.0 [4+Na]+ .
Tris-1,3,5-{w-(2’-O-Me-5’-O-{[2’-O-Me-5’-O-(Dmtr)-4-N-acetylcyto-
sin-3’-yl](2-cyanoethyloxy)thiophosphoryl}uridinyl-3’-O-succiny-
loxy)octa(ethylene glycol)-a-oxymethyl}benzene, tris-
(mUpCneSmCAc-ODmtr) homostar (7): Tris(2’-methyluridine) homo-
star 4 (422 mg, 0.188 mmol) and compound 6C (678 mg,
0.846 mmol, 4.5 equiv) were co-evaporated from CH3CN (3Õ10 mL)
in vacuo. To the residue was added 0.25m ETT in CH3CN (6.77 mL,
1.69 mmol, 9 equiv), and after 40 min, PADS (1.71 g, 5.65 mmol,
30 equiv) and pyridine (6.8 mL) were added. After a further 60 min
the solvent was stripped off under reduced pressure and the resi-
due fractionated through a column of silanised silica, eluting with
a gradient of water–THF, plus sat. NaHCO3 (0.5 vol%). The appropri-
ate fractions were combined and the THF evaporated in vacuo.
The resultant emulsion was extracted with CH2Cl2 (100 mLÕ4), the
organic layer dried over Na2SO4, and then evaporated to dryness.
The residue was fractionated through silanised silica, eluting with
a gradient of water–CH3CN, plus sat. NaHCO3 (0.5 vol%). The ap-
propriate fractions were extracted as before to afford compound 7
(538 mg, 64%). Rf (CH3OH–CH2Cl2 1:9) 0.41; intermediate tris(phos-
phite triester) 0.54; 1H NMR (400 MHz, D6-acetone): d=10.38 (br s,
1.5H; NH), 10.25 (s, 1.5H; NH), 10.19 (s, 1.5H; NH), 10.15 (br s,
1.5H; NH), 8.49 (d, J=7.4 Hz, 3H; C CH), 7.75 (d, J=8.2 Hz, 1.5H; U
CH), 7.64 (d, J=8.2 Hz, 1.5H; U CH), 7.54–7.51 (m, 6H; Dmtr CH),
7.42–7.36 (m, 18H; Dmtr CH), 7.33–7.30 (m, 3H; Dmtr CH), 7.28 (s,
3H; Hub CH), 7.13 (d, J=7.2 Hz, 1.5H; C CH), 7.12 (d, J=7.4 Hz,
1.5H; C CH), 6.97–6.93 (m, 12H; Dmtr CH), 6.07–6.04 (m, 3H; 1’-
CH), 5.99–5.96 (m, 3H; 1’-CH), 5.71 (d, J=7.7 Hz, 1.5H; U CH), 5.70
(d, J=7.8 Hz, 1.5H; U CH), 5.37–5.26 (m, 2H; 2Õ3’-CH), 4.56 (s, 6H;
Hub-CH2O), 4.53–4.37 (m, 9H; U 4’-CH + C 4’-CH + POCHHCH2CN),
4.36–4.15 (m, 21H; U 2’-CH + C 2’-CH + 5’-CH2 + POCHHCH2CN +
Suc-OCH2), 3.84 (s, 9H; Dmtr OCH3), 3.83 (s, 9H; Dmtr OCH3), 3.69–
3.53 (m, 105H; CH2O + 5’-CH2 + 2’-OCH3), 3.41 (s, 4.5H; 2’-OCH3),
3.40 (s, 4.5H; 2’-OCH3), 3.01 (t, J=7.2 Hz, 3H; CH2CN), 2.9–2.87 (m,
3H; CH2CN), 2.76–2.73 (m, 6H; Suc CH2), 2.70–2.67 (m, 6H; Suc
CH2), 2.25 (s, 4.5H; Ac CH3), 2.24 ppm (s, 4.5H; Ac CH3) ;
13C NMR
(101 MHz, D6-acetone): d=171.89 (3C; C=O), 171.45 (3C; C=O),
170.66 (3C; C=O), 163.09 (3C; U/C C), 162.68 (1.5C; U/C C), 162.64
(1.5C; U/C C), 158.92 (6C; Dmtr C), 154.71 (1.5C; C C), 154.60
(1.5C; C C), 150.47 (1.5C; U C), 150.44 (1.5C; U C), 144.44 (1.5C; C
CH), 144.30 (1.5C; C CH), 144.27 (1.5C; Dmtr C), 144.12 (1.5C; Dmtr
C), 140.02 (3C; U 6-CH), 139.00 (3C; Hub C), 135.43 (1.5C; Dmtr C),
135.33 (1.5C; Dmtr C), 135.19 (1.5C; Dmtr C), 135.15 (1.5C; Dmtr
C), 130.27 (6C; Dmtr CH), 130.18 (6C; Dmtr CH), 128.48 (3C; Dmtr
CH), 128.40 (3C; Dmtr CH), 128.02 (6C; Dmtr CH), 127.18 (3C; Dmtr
CH), 125.70 (3C; Hub CH), 117.59 (1.5C; CN), 117.31 (1.5C; CN),
113.27 (12C; Dmtr CH), 102.65 (1.5C; U 5-CH), 102.52 (1.5C; U 5-
CH), 96.15 (3C; C CH), 88.80 (1.5C; 1’-CH), 88.51 (1.5C; 1’-CH),
88.04 (1.5C; 1’-CH), 87.99 (1.5C; 1’-CH), 87.08 (1.5C; Dmtr C), 87.06
(1.5C; Dmtr C), 82.09 (1.5C; Ri CH), 81.78 (1.5C; Ri CH), 80.91 (3C;
Ri CH), 80.79 (3C; Ri CH), 80.15–80.00 (m, 3C; Ri CH), 73.51 (1.5C;
Ri CH), 73.28 (1.5C; Ri CH), 72.54 (3C; Hub-CH2O), 70.58 (3C; Ri
CH), 70.35 (39C; CH2), 69.64 (3C; CH2O), 68.72 (3C; CH2O), 67.42–
67.10 (3C; U 5’-CH2), 63.75–63.48 (m, 6C; CH2O + POCH2CH2CN),
60.57 (1.5C; C 5’-CH2), 60.49 (1.5C; C 5’-CH2), 58.40 (1.5C; 2’-OCH3),
58.33 (1.5C; 2’-OCH3), 58.13 (1.5C; 2’-OCH3), 57.83 (1.5C; 2’-OCH3),
54.81 (3C; Dmtr OCH3), 54.79 (3C; Dmtr OCH3), 28.67 (6C; Suc
CH2), 24.13 (1.5C; Ac CH3), 24.05 (1.5C; Ac CH3), 19.07–18.90 ppm
(m, 3C; CH2CN);
31P NMR (162 MHz, D6-acetone) d=67.33 (0.39P),
67.11 ppm (0.61P); MS (MALDI-ToF+): m/z calcd for
[C207H269N18NaO79P3S3]
+ : 4484.59; found: 4484.1 [7+Na+H2O]
+ .
Tris(mUpCneSmCAc-OH) homostar (10): Tris(DmtrO-2-mer) homostar
7 (192 mg, 43 mmol) was placed in CH2Cl2 (1 mL), to which pyrrole
(35 mL) then DCA (35 mL) were added. After 60 min the reaction
was complete by TLC and 1m triethylammonium bicarbonate
(TEAB, 0.5 mL) was added, followed by sufficient CH3CN to give
a clear solution. The solution was concentrated at reduced pres-
sure until all CH2Cl2 had evaporated, then silanised silica (10 mL)
was added to the remaining solution followed by the slow addi-
tion of water (90 mL) with gentle swirling, plus 1m TEAB (1 mL).
The silica was collected in a glass sinter funnel, and the pad was
washed with water (50 mL), then CH3CN–water (1:3 v/v, 160 mL
plus 1.5 mL TEAB) and the filtrate was discarded. Next the silica
was washed with CH3CN (150 mL) and the filtrate evaporated to
dryness. The residue (156 mg) was taken up in CHCl3 (20 mL) and
to the swirled solution was added normal phase silica (10 mL). The
silica was collected in a glass sinter funnel, the pad was washed
with further CHCl3 (130 mL) and the filtrate discarded. Finally the
silica was washed with CH3OH–CHCl3 (1:9 v/v, 150 mL) and the fil-
trate evaporated to dryness to afford compound 10 (118 mg,
77%). Rf(EtOH–CHCl3 1:9) 0.19;
1H NMR (500 MHz, CDCl3–CD3OD 2:1
v/v): d=8.42 (d, J=7.5 Hz, 1.5H; C CH), 8.41 (d, J=7.6 Hz, 1.5H; C
CH), 7.63 (d, J=8.1 Hz, 1.5H; U CH), 7.59 (d, J=8.1 Hz, 1.5H; U CH),
7.402 (d, J=7.5 Hz, 1.5H; C CH), 7.397 (d, J=7.6 Hz, 1.5H; C CH),
7.21 (s, 3H; Hub CH), 5.98 (d, J=3.7 Hz, 3H; Ri 1’-CH), 5.91 (d, J=
4.7 Hz, 1.5H; Ri 1’-CH), 5.90 (d, J=4.9 Hz, 1.5H; Ri 1’-CH), 5.75 (d,
J=8.1 Hz, 1.5H; U CH), 5.72 (d, J=8.1 Hz, 1.5H; U CH), 5.21 (t, J=
5.2 Hz, 3H; U 3’-CH) 5.03–4.97 (m, 3H; C 3’-CH), 4.52 (s, 6H; Hub-
CH2O), 4.45–4.23 (m, 18H; POCH2CH2CN + U 5’- CH2 + C 4’-CH +
U 4’-CH), 4.21–4.19 (m, 6H; Suc-OCH2), 4.15 (br t, J=4.3 Hz, 1.5H; U
2’-CH), 4.14 (br t, J=4.4 Hz, 1.5H; U 2’-CH), 4.04 (dd, J=4.9, 1.3 Hz,
1.5H; C 2’-CH), 4.03 (dd, J=5.3, 1.3 Hz, 1.5H; C 2’-CH), 3.95–3.91
(m, 3H; 5’-CHH), 3.78–3.73 (m, 3H; 5’-CHH), 3.67 (t, J=4.8 Hz, 6H;
CH2O), 3.65–3.59 (m, 84H; CH2O), 3.53 (s, 4.5H; 2’-OCH3), 3.50 (s,
4.5H; 2’-OCH3), 3.39 (s, 9H; 2’-OCH3), 2.85–2.82 (m, 6H; CH2CN),
2.72–2.69 (m, 6H; Suc CH2CH2), 2.67–2.64 (m, 6H; Suc CH2CH2),
2.17 ppm (s, 9H; Ac CH3) ;
13C NMR (126 MHz, CDCl3–CD3OD 2:1 v/
v): d=172.40 (3C; C=O), 171.75 (1.5C; C=O), 171.71 (1.5C; C=O),
171.56 (3C; C=O), 164.15 (3C; U/C C), 162.83 (3C; U/C C), 156.09
(3C; C C), 150.52 (3C; U C), 145.39 (3C; C CH), 140.21 (3C; U 6-CH),
138.47 (3C; Hub C), 126.40 (3C; Hub CH), 117.03 (1.5C; CN), 116.96
(1.5C; CN), 102.79 (1.5C; U 5-CH), 102.73 (1.5C; U 5-CH), 97.40
(1.5C; C CH), 97.34 (1.5C; C CH), 89.22 (1.5C; C 1’-CH), 89.10 (1.5C;
C 1’-CH), 88.08 (1.5C; U 1’-CH), 88.02 (1.5C; U 1’-CH), 83.29–83.19
(m, 3C; U 4’-CH), 82.17 (3C; C 2’-CH), 81.09 (1.5C; U 2’-CH), 81.04
(1.5C; U 2’-CH), 80.08–79.97 (m, 3C; C 4’-CH), 74.50–74.42 (m, 3C;
C 3’-CH), 72.93 (3C; Hub-CH2O), 70.35 (39C; CH2O), 70.18 (3C; U 3’-
CH), 69.43 (3C; CH2O), 68.87 (3C; CH2O), 66.70 (br, 3C; U 5’-CH2),
63.91 (3C; SucOCH2), 63.14–63.07 (m, 3C; POCH2CH2CN), 59.65 (3C;
C 5’-CH2), 58.81 (3C; 2’-OCH3), 58.57 (1.5C; 2’-OCH3), 58.54 (1.5C;
2’-OCH3), 28.76 (6C; Suc CH2), 24.24 (3C; Ac CH3), 19.22–19.10 ppm
(m, 3C, CH2CN);
31P NMR (202 MHz, CDCl3–CD3OD 2:1 v/v): d=
67.81 (0.44P), 67.59 ppm (0.56P); MS (MALDI-ToF+): m/z calcd for
[C144H214N18NaO72P3S3]
+=3537.20; found: 3538.3 [10+H]+ .
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Tris(mUpCneSmCAcpCneSmCAcpCneSmABzpCneSmUpCneSmU-OH) ho-
mostar (21)—typical chain extension cycle: Tris(HO-5-mer) homo-
star 18 (1.286 g, 0.171 mmol) was dissolved in DMF (4 mL) to
which was added CH3CN (20 mL) and the solution evaporated in
vacuo; this was repeated with DMF (2 mL) plus CH3CN (20 mL),
and finally with neat CH3CN (20 mL). Phosphoramidite 6
U (585 mg,
0.769 mmol, 4.5 equiv) was then added to the residue followed by
0.25m ETT in CH3CN (6.2 mL, 1.55 mmol, 9 equiv). After 35 min
PADS (465 mg, 1.55 mmol, 9 equiv) and pyridine (6.2 mL) were
added, and after a further 35 min the reaction was diluted into
CH3OH–CH3CN (3:17 v/v) and poured into the OSN rig. Once 12 di-
avolumes had permeated, the retentate was evaporated to give
crude 5’-Dmtr homostar 20 (1.779 g) as a brown glass.
Partially purified tris(DmtrO-6-mer) homostar 20 (1.708 g) was
placed in CH2Cl2 (28 mL), to which was added pyrrole (0.48 mL)
then DCA (0.28 mL). After 45 min the reaction was complete by
TLC and pyridine (0.28 mL) was added. The mixture was diluted
with CH3CN (100 mL) and the liquid concentrated until all the
CH2Cl2 had evaporated. To this solution was then added CH3OH
(20 mL), the solution was diluted with further CH3OH–CH3CN (3:17
v/v) containing pyridinium.DCA (0.5 vol%) and 5 diavolumes were
permeated. The flux was observed to drop significantly, so this was
followed by 10 diavolumes CH3OH–CH3CN (1:4 v/v) when the flux
improved. The retentate was evaporated to dryness, and the resid-
ual glass was re-dissolved in CH2Cl2–CH3OH (10 mL). The solution
was added dropwise to briskly stirred diethyl ether (300 mL), and
the precipitate collected to afford tris(HO-6-mer) homostar 21
(1.394 g, 98%) as a brown powder. 31P NMR (202 MHz, CDCl3-
CD3OD 2:1 v/v): d=67.8–67.1 ppm (m, 15P); MS (MALDI-ToF+): m/
z calcd for [C330H429N66NaO153P15S15]
+ : 8734.0; found: 8728 [21+
Na]+ .
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